Saudi Arabia Cardiovascular Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The saudi arabia cardiovascular devices market size is projected to expand from USD 527.33 million in 2025 and USD 554.80 million in 2026 to USD 715.19 million by 2031, registering a CAGR of 5.21% between 2026 to 2031. This report is Segmented by by Device Type (Diagnostic and Monitoring Devices and Therapeutic and Surgical Devices), Application (Coronary Artery Disease, Arrhythmia and More), End User (Hospitals & Cardiac Centers, Ambulatory Surgical Centers and More) and Geography. The Report Offers the Value (in USD) for all the Above.

Saudi Arabia Cardiovascular Devices Market Trends and Insights

Rising Burden of CVD & Diabetes Comorbidity

Cardiovascular disease accounts for more than 45% of deaths in Saudi Arabia, and diabetes prevalence stands at 23.1% among adults, creating a dual epidemic that pushes complex percutaneous interventions to the forefront.

Coronary stent cases are increasingly supported by intravascular ultrasound to optimize deployment in calcified lesions common in diabetic vessels. Heart-failure clinics now rely on cardiac resynchronization devices and pulmonary pressure sensors to manage diabetic cardiomyopathy. National Transformation Program screening targets people aged 40-60. Yet, almost half of diabetics remain undiagnosed until an acute coronary event, highlighting the role for point-of-care biomarker kits and mobile echo vans in provincial areas. The sustained disease load secures long-run momentum for the Saudi Arabia cardiovascular devices market.

Large-Scale Vision 2030 Investments in Cardiac Infrastructure

The 2024 national budget reserved SAR 260 billion (USD 69.3 billion) for health and social development. Five new hospitals with 963 cardiovascular-ready beds will open by 2025, while cluster models integrate peripheral clinics via tele-cardiology networks. These physical and digital expansions accelerate placements of cath-lab imaging, portable ultrasound, and remote patient monitoring kits. Government procurement increasingly embeds local-content clauses, encouraging multinationals to establish technical transfer agreements with Saudi factories. As infrastructure matures, high-acuity centers in Riyadh and Jeddah become referral anchors for complex structural heart and electrophysiology cases.

Fragmented Procurement & Lengthy SFDA Approvals

Twenty autonomous health clusters each run distinct tenders, forcing manufacturers to navigate parallel formularies and stretching product launch timelines to 18 months on average. SFDA, limited to processing roughly 200 Class III filings a year, confronts backlogs that postpone next-generation valve and ICD introductions. Exclusive contracts in certain clusters restrict volume scale, discouraging local inventory hubs and inflating last-mile logistics. The complexity chips 0.8 percentage points from the Saudi Arabia cardiovascular devices market CAGR.

Other drivers and restraints analyzed in the detailed report include:

• Mandatory Private Health Insurance Expanding Procedure Access
• Localization Incentives for In-Kingdom Device Manufacturing
• High Price Pressure in Public Tenders

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Therapeutic & surgical systems captured 64.20% of 2025 revenue, underscoring the centrality of stents, valve kits, and rhythm-management implants in the Saudi Arabia cardiovascular devices market. Drug-eluting stents remain workhorses, yet bioresorbable scaffolds appeal to younger cohorts seeking vessel restoration without permanent metal. Leadless pacemakers such as Micra AV2, introduced locally in 2025, answer infection concerns and reduce pocket complications.

Diagnostic & monitoring devices, while smaller, are forecast to advance at a 5.93% CAGR through 2031, fueled by SEHA Virtual Hospital reimbursements that pay for wearable ECG patches and implantable loop recorders. GE’s rollout of 1,000 bedside monitors and 500 Portrait VSM wearables has already cut unplanned readmissions by nearly one-quarter. Non-invasive imaging modalities such as FFR-CT, cardiac MRI, and handheld ultrasound further position the Saudi Arabia cardiovascular devices market for sustained long-term growth as clinicians prioritize precision triage over indiscriminate catheterization.

Complete Report Scope:

• By Device Type
  • Diagnostic & Monitoring Devices
    • ECG Systems
    • Remote Cardiac Monitors & Patches
    • Cardiac MRI
    • Cardiac CT
    • Echocardiography / Ultrasound
    • Fractional Flow Reserve (FFR) Systems
  • Therapeutic & Surgical Devices
    • Coronary Stents
      • Drug-Eluting Stents
      • Bare-Metal Stents
      • Bioresorbable Stents
    • Catheters
      • PTCA Balloon Catheters
      • IVUS/OCT Catheters
    • Cardiac Rhythm Management
      • Pacemakers
      • Implantable Cardioverter Defibrillators
      • Cardiac Resynchronization Therapy Devices
    • Heart Valves
      • TAVR/TAVI
      • Mechanical Valves
      • Tissue/Bioprosthetic Valves
    • Ventricular Assist Devices
    • Artificial Hearts
    • Grafts & Patches
    • Other Cardiovascular Surgical Devices
• By Application
  • Coronary Artery Disease
  • Arrhythmia
  • Heart Failure
  • Structural Heart Disease
  • Hypertension
  • Others
• By End-User
  • Hospitals
  • Home-Care Settings
  • Others

List of Companies Covered in this Report:

• Abbott Laboratories
• B. Braun
• BIOTRONIK
• Boston Scientific
• Cook Group
• Edward Lifesciences
• GE HealthCare Technologies Inc.
• Getinge AB (Maquet)
• Huma Therapeutics Ltd.
• Jamjoom Medical Industries
• Johnson & Johnson Services, Inc. (Cordis / Biosense Webster)
• LivaNova
• Medtronic
• Meril Life Science
• MicroPort
• Koninklijke Philips
• Siemens Healthineers
• Terumo
• W. L. Gore & Associates
• WCS Global Medical Technology

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support